

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 July 2021 (08.07.2021)



(10) International Publication Number
WO 2021/138600 A1

(51) International Patent Classification:
C12N 15/11 (2006.01)

(21) International Application Number:
PCT/US2020/067729

(22) International Filing Date:
31 December 2020 (31.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/956,033 31 December 2019 (31.12.2019) US

(71) Applicants: **FRED HUTCHINSON CANCER RESEARCH CENTER** [US/US]; 1100 Fairview Avenue North, Seattle, Washington 98109 (US). **TIDAL THERAPEUTICS, INC.** [US/US]; 700 Main Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **STEPHAN, Matthias**; 1100 Fairview Avenue North, Seattle, Washington 98109 (US). **NIELSEN, Ulrik**; 700 Main Street, Cambridge, Massachusetts 02139 (US).


(74) Agent: **WINGER, C. Rachal** et al.; Lee & Hayes PC, 601 W. Riverside Ave., Suite 1400, Spokane, Washington 99201 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: NANOPARTICLE SYSTEMS TO STIMULATE AND MAINTAIN IMMUNE SYSTEM RESPONSIVENESS AT TREATMENT SITES

FIG. 1A



(57) Abstract: Nanoparticle systems that genetically modify monocytes/macrophages in vivo to (1) recruit additional immune cells to a treatment site; (2) remain activated at the treatment site providing an on-going stimulatory signal to other immune cells; and (3) secrete bispecific immune-cell engaging antibodies that bind antigens on cells of interest at the treatment site and also bind and activate the recruited immune cells to destroy the bound cell. The systems can also inhibit the activity of transforming growth factor beta (TGFβ).

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*